Sclerosis: all 3,103 studies

Page 6 of 32. Open to participants first (314), then studies with results posted, then the rest; newest registration first within each.

• Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple SclerosisCompletedNCT02738775Phase 2Results posted
• Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple SclerosisCompletedNCT02727907Phase 2/3Results posted
• Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01)CompletedNCT02720107Phase 4Results posted
• A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS)CompletedNCT02714036Phase 1/2Results posted
• A TSEC for Symptom Management in Menopausal Women With Multiple SclerosisCompletedNCT02710214Phase 2Results posted
• ALS Reversals - Lunasin RegimenCompletedNCT02709330Phase 2Results posted
• Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)CompletedNCT02688985Phase 3Results posted
• Evaluation of a Modified Paleolithic Dietary Intervention in the Treatment of Relapsing-Remitting Multiple SclerosisCompletedNCT02687919Not applicableResults posted
• The Use of Airway Clearance Devices in ALSCompletedNCT02682030Not applicableResults posted
• DESIPHER_Speech Degradation as an Indicator of Physiological Degeneration in ALSCompletedNCT02675075Results posted
• Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDYTerminatedNCT02665221Phase 4Results posted
• Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic SclerosisCompletedNCT02663895Phase 2Results posted
• Effects of Teriflunomide (Aubagio) on Cognitive and Vocational Outcomes in Multiple SclerosisCompletedNCT02651545Results posted
• A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)CompletedNCT02637856Phase 3Results posted
• A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1CompletedNCT02634307Phase 3Results posted
• An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)CompletedNCT02623699Phase 3Results posted
• Treating Anorectal Dysfunction in MSTerminatedNCT02609607Phase 2Results posted
• Effects of Functional Electrical Stimulation Cycling Versus Cycling Only on Walking and Quality of Life in MSCompletedNCT02606604Not applicableResults posted
• Plegridy Satisfaction Study in ParticipantsCompletedNCT02587065Phase 4Results posted
• A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple SclerosisCompletedNCT02576717Phase 3Results posted
• Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)CompletedNCT02555215Phase 3Results posted
• A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple SclerosisCompletedNCT02545868Phase 3Results posted
• A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)CompletedNCT02544763Phase 3Results posted
• An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)CompletedNCT02544750Phase 3Results posted
• tDCS and Cognition in Adults With Multiple Sclerosis or EncephalitisCompletedNCT02538094Not applicableResults posted
• Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).CompletedNCT02525874Phase 3Results posted
• Wearable Lower Extremity Exoskeleton to Promote Walking in Persons With Multiple SclerosisCompletedNCT02519244Not applicableResults posted
• Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®CompletedNCT02499900Phase 4Results posted
• Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a YearCompletedNCT02496767Phase 3Results posted
• Taking Charge of Systemic SclerosisCompletedNCT02494401Not applicableResults posted
• Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral SclerosisCompletedNCT02479802Phase 2Results posted
• Augmenting Cerebral Blood Flow to Treat Established Multiple SclerosisTerminatedNCT02466074Phase 2Results posted
• Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic SclerosisTerminatedNCT02465437Phase 2Results posted
• Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT02460679Phase 2Results posted
• A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)CompletedNCT02453256Phase 3Results posted
• Clinical Trial of Ezogabine (Retigabine) in ALS SubjectsCompletedNCT02450552Phase 2Results posted
• Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MSTerminatedNCT02446886Phase 4Results posted
• HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT02437110Phase 1Results posted
• BG00012 and Delay of Disability Progression in Secondary Progressive Multiple SclerosisTerminatedNCT02430532Phase 3Results posted
• Tecfidera Slow-Titration StudyTerminatedNCT02428231Phase 3Results posted
• Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple SclerosisCompletedNCT02425644Phase 3Results posted
• Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving TecfideraCompletedNCT02410278Phase 4Results posted
• Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMSCompletedNCT02410200Phase 2Results posted
• Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple SclerosisCompletedNCT02391961Phase 2Results posted
• Long Term Effect of Buspirone on Esophageal Function and Esophageal Symptoms in Patients With Systematic Sclerosis (SSc)CompletedNCT02363478Early Phase 1Results posted
• Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.TerminatedNCT02343159Phase 4Results posted
• Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) ParticipantsTerminatedNCT02342704Phase 4Results posted
• Theory Based Intervention Program to Support Physical Activity for Individuals With Multiple Sclerosis: a Case SeriesCompletedNCT02335450Not applicableResults posted
• ACTH for Fatigue in Multiple Sclerosis PatientsCompletedNCT02315872Phase 3Results posted
• Long-term Follow-up of Fingolimod Phase II Study PatientsCompletedNCT02307838Phase 4Results posted
• Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple SclerosisTerminatedNCT02296346Not applicableResults posted
• Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)CompletedNCT02294058Phase 3Results posted
• Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH)CompletedNCT02290613Phase 2Results posted
• Effects of Acthar on Recovery From Cognitive Relapses in MSCompletedNCT02290444Phase 3Results posted
• A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)CompletedNCT02288091Phase 1Results posted
• A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to PlaceboCompletedNCT02284568Phase 2Results posted
• Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple SclerosisCompletedNCT02280096Phase 2Results posted
• Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)CompletedNCT02258217Not applicableResults posted
• Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409CompletedNCT02255656Phase 4Results posted
• Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™CompletedNCT02254304Phase 4Results posted
• Exploring the Use of Non-invasive Neuromodulation Combined With Exercise in People With Advanced Multiple Sclerosis (MS)CompletedNCT02252666Not applicableResults posted
• Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other TherapiesTerminatedNCT02241785Phase 4Results posted
• Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT02238626Phase 2Results posted
• Adherence in Pediatric Multiple SclerosisCompletedNCT02234713Not applicableResults posted
• Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular RisksCompletedNCT02232061Phase 4Results posted
• Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple SclerosisCompletedNCT02219932Phase 3Results posted
• A Study of the Effectiveness of Fampridine in Improving Upper Limb Function in MSCompletedNCT02208050Phase 4Results posted
• Everolimus for Cancer With TSC1 or TSC2 MutationCompletedNCT02201212Phase 2Results posted
• Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple SclerosisCompletedNCT02201108Phase 3Results posted
• Blood Lactate Concentrations With and Without Exercise in Parkinson's Disease and Multiple Sclerosis PatientsCompletedNCT02184494Not applicableResults posted
• Developing and Testing a Comprehensive MS Spasticity Management ProgramCompletedNCT02170779Phase 2Results posted
• A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic SclerosisCompletedNCT02161406Phase 2Results posted
• Neuromuscular Electrical Stimulation and Mobility in Multiple SclerosisCompletedNCT02152085Not applicableResults posted
• Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple SclerosisCompletedNCT02133664Phase 1/2Results posted
• Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In GermanyCompletedNCT02125604Phase 4Results posted
• Therapy in Amyotrophic Lateral Sclerosis (TAME)CompletedNCT02118727Phase 2Results posted
• RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl FumarateTerminatedNCT02117050Phase 4Results posted
• Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.CompletedNCT02097849Phase 2Results posted
• Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple SclerosisCompletedNCT02090413Phase 4Results posted
• Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple SclerosisCompletedNCT02086188Phase 4Results posted
• A Study of Rebif® in Subjects With Relapsing Multiple SclerosisCompletedNCT02064816Phase 4Results posted
• Safety of Simvastatin in LAM and TSCCompletedNCT02061397Phase 1/2Results posted
• Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MSCompletedNCT02048072Phase 4Results posted
• Efficacy and Safety Study of Ozanimod in Relapsing Multiple SclerosisCompletedNCT02047734Phase 3Results posted
• A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)TerminatedNCT02045732Phase 1Results posted
• A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple SclerosisTerminatedNCT02038049Phase 2Results posted
• Electric Stimulation of the Eye to Improve Vision After TraumaCompletedNCT02019927Not applicableResults posted
• Rebif® Rebidose® Versus Rebiject II® Ease-of-UseCompletedNCT02019550Phase 4Results posted
• Effects of Dalfampridine on Cognition in Multiple SclerosisCompletedNCT02006160Phase 2/3Results posted
• Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple SclerosisCompletedNCT01982942Phase 2Results posted
• ATX-MS-1467 in Multiple SclerosisCompletedNCT01973491Phase 2Results posted
• MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCVCompletedNCT01970410Phase 4Results posted
• A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis PatientsCompletedNCT01964547Phase 4Results posted
• Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)TerminatedNCT01963611Phase 2Results posted
• Amyotrophic Lateral Sclerosis Registry Rhineland-PalatinateCompletedNCT01955369Results posted
• ACTH in Progressive Forms of MSTerminatedNCT01950234Phase 2Results posted
• The Effects of Ankle Foot Orthoses (AFOs) on Mobility in Persons With Multiple Sclerosis (MS)CompletedNCT01947582Not applicableResults posted
• Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)CompletedNCT01939002Phase 3Results posted
• Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)CompletedNCT01933334Phase 2Results posted
• Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice PatternsCompletedNCT01930799Phase 4Results posted

← Sclerosis overview